766529-90-2

Upstream product

• 766529-97-9 (4E)-(3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-5-hydroxy-4-[3-(methoxymethoxy)propylidene]cyclohexanone 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 766529-88-8 (1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 766529-96-8 [(4E)-(1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,5-dihydroxy-4-[3-(methoxymethoxy)propylidene]cyclohexyl]methanol 
• 766529-89-9 (4E)-(1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-4-[3'-(methoxymethoxy)propylidene]bicyclo[3.2.1]octan-7-one 
• 78365-43-2 1-bromo-3-(methoxymethoxy)propane 
• 77-95-2 D-(-)-quinic acid 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 

Relevant academic research and scientific papers

New 2-alkylidene 1α,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: Synthesis and biological evaluation of 2-(3′-alkoxypropylidene) and 2-(3′-hydroxypropylidene) derivatives

In a search for novel vitamin D compounds of potential therapeutic value, E- and Z-isomers of 1α,25-dihydroxy-2-(3′-hydroxypropylidene)-19- norvitamin D3, as well as a derivative of the former compound possessing a 3′-(methoxymethoxy)propyliden

Vitamin D analogs for obesity prevention and treatment

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α

2-PROPYLIDENE-19-NOR-VITAMIN D COMPOUNDS

2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium